Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses

Journal of Virology

Volumn 79, Issue 9, 2005, Pages 5537-5547

  Chen, Xuemin ^a   Rock, Michael T ^a   Hammonds, Jason ^a   Tartaglia, James ^b   Shintani, Ayumi ^a   Currier, Jeff ^c   Slike, Bonnie ^c   Crowe Jr , James E ^a   Marovich, Mary ^c   Spearman, Paul ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Aventis Pasteur   (Canada)

^c US Military HIV Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAG PROTEIN; GAMMA INTERFERON; GLYCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CANARYPOX VIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ENVELOPE GENE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION; HOST CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; MODEL; MOUSE; MYRISTYLATION; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STAINING; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS PARTICLE;

AIDS VACCINES; ANIMALS; ANTIBODY SPECIFICITY; CANARYPOX VIRUS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENE PRODUCTS, ENV; GENES, GAG; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; POXVIRIDAE;

EID: 20244369446     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.9.5537-5547.2005     Document Type: Article

References (49)

1. Amara, R. R., F. Villinger, S. I. Staprans, J. D. Altman, D. C. Montefiori, N. L. Kozyr, Y. Xu, L. S. Wyatt, P. L. Earl, J. G. Herndon, H. M. McClure, B. Moss, and H. L. Robinson. 2002. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76:7625-7631.
2. Belshe, R. B., G. J. Gorse, M. J. Mulligan, T. G. Evans, M. C. Keefer, J. L. Excler, A. M. Duliege, J. Tartaglia, W. I. Cox, J. McNamara, K. L. Hwang, A. Bradney, D. Montefiori, K. J. Weinhold, et al. 1998. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 12:2407-2415.
3. Belshe, R. B., C. Stevens, G. J. Gorse, S. Buchbinder, K. Weinhold, H. Sheppard, D. Stablein, S. Self, J. McNamara, S. Frey, J. Flores, J. L. Excler, M. Klein, R. E. Habib, A. M. Duliege, C. Harro, L. Corey, M. Keefer, M. Mulligan, P. Wright, C. Celum, F. Judson, K. Mayer, D. McKirnan, M. Marmor, and G. Woody. 2001. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 183:1343-1352.
4. mac251: dependence on route of challenge exposure. J. Virol. 72:4170-4182.
5. Buseyne, F., S. Le Gall, C. Boccaccio, J. P. Abastado, J. D. Lifson, L. O. Arthur, Y. Riviere, J. M. Heard, and O. Schwartz. 2001. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med. 7:344-349.
6. Caley, I. J., M. R. Betts, N. L. Davis, R. Swanstrom, J. A. Frelinger, and R. E. Johnston. 1999. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 17:3124-3135.
7. Caley, I. J., M. R. Betts, D. M. Irlbeck, N. L. Davis, R. Swanstrom, J. A. Frelinger, and R. E. Johnston. 1997. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71:3031-3038.
8. Davis, N. L., A. West, E. Reap, G. MacDonald, M. Collier, S. Dryga, M. Maughan, M. Connell, C. Walker, K. McGrath, C. Cecil, L. H. Ping, J. Frelinger, R. Olmsted, P. Keith, R. Swanstrom, C. Williamson, P. Johnson, D. Montefiori, and R. E. Johnston. 2002. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53:209-211.
9. + T cells for recall of viral clearing responses against influenza virus. J. Virol. 76:4212-4221.
10. Earl, P. L., L. S. Wyatt, D. C. Montefiori, M. Bilska, R. Woodward, P. D. Markham, J. D. Malley, T. U. Vogel, T. M. Allen, D. I. Watkins, N. Miller, and B. Moss. 2002. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 294:270-281.
11. Fang, Z. Y., I. Kuli-Zade, and P. Spearman. 1999. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate. J. Infect. Dis. 180:1122-1132.
12. Fang, Z. Y., K. Limbach, J. Tartaglia, J. Hammonds, X. Chen, and P. Spearman. 2001. Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. Virology 291:272-284.
13. Ferrari, G., C. Berend, J. Ottinger, R. Dodge, J. Bartlett, J. Toso, D. Moody, J. Tartaglia, W. I. Cox, E. Paoletti, and K. J. Weinhold. 1997. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. Blood 90:2406-2416.
14. Ferrari, G., W. Humphrey, M. J. McElrath, J. L. Excler, A. M. Duliege, M. L. Clements, L. C. Corey, D. P. Bolognesi, and K. J. Weinhold. 1997. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA 94:1396-1401.
15. Fonteneau, J. F., D. G. Kavanagh, M. Lirvall, C. Sanders, T. L. Cover, N. Bhardwaj, and M. Larsson. 2003. Characterization of the MHC class I crosspresentation pathway for cell associated antigens by human dendritic cells. Blood 102:4448-4455.
16. Freed, E. O. 1998. HIV-1 Gag proteins: diverse functions in the virus life cycle. Virology 251:1-15.
17. Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Cote, R. L. Rich, D. G. Myszka, and W. I. Sundquist. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65.
18. Gottlinger, H. G., T. Dorfman, E. A. Cohen, and W. A. Haseltine. 1993. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA 90:7381-7385.
19. Haffar, O., J. Garrigues, B. Travis, P. Moran, J. Zarling, and S. L. Hu. 1990. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64:2653-2659.
20. Hanke, T., A. J. McMichael, M. Mwau, E. G. Wee, I. Ceberej, S. Patel, J. Sutton, M. Tomlinson, and R. V. Samuel. 2002. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 20:1995-1998.
21. Kang, C. Y., L. Luo, M. A. Wainberg, and Y. Li. 1999. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biol. Chem. 380:353-364.
22. Karacostas, V., K. Nagashima, M. A. Gonda, and B. Moss. 1989. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc. Natl. Acad. Sci. USA 86:8964-8967.
23. Laird, N. M., and J. H. Ware. 1982. Random-effects models for longitudinal data. Biometrics 38:963-974.
24. + cell-depleted BALB/c mice. J. Virol. 70:3084-3092.
25. Larsson, M., J. F. Fonteneau, and N. Bhardwaj. 2003. Cross-presentation of cell-associated antigens by dendritic cells. Curr. Top. Microbiol. Immunol. 276:261-275.
26. Larsson, M., J. F. Fonteneau, M. Lirvall, P. Haslett, J. D. Lifson, and N. Bhardwaj. 2002. Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS 16:1319-1329.
27. Letvin, N. L. 2002. Strategies for an HIV vaccine. J. Clin. Investig. 110:15-20.
28. Luo, L., Y. Li, and C. Yong Rang. 2003. Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells. Virus Res. 92:75-82.
29. Marovich, M. A., J. R. Mascola, M. A. Eller, M. K. Louder, P. A. Caudrelier, R. El-Habib, S. Ratto-Kim, J. H. Cox, J. R. Currier, B. L. Levine, C. H. June, W. B. Bernstein, M. L. Robb, B. Schuler-Thurner, R. M. Steinman, D. L. Birx, and S. Schlesinger-Frankel. 2002. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. J. Infect. Dis. 186:1242-1252.
30. Mata, M., P. J. Travers, Q. Liu, F. R. Frankel, and Y. Paterson. 1998. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J. Immunol. 161:2985-2993.
31. McMichael, A. J., and T. Hanke. 2003. HIV vaccines 1983-2003. Nat. Med. 9:874-880.
32. Nilsson, C., G. Sutter, L. Walther-Jallow, P. ten Haaft, L. Akerblom, J. Heeney, V. Erfle, P. Bottiger, G. Biberfeld, and R. Thorstensson. 2002. Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques. J. Gen. Virol. 83:807-818.
33. Norbury, C. C., S. Basta, K. B. Donohue, D. C. Tscharke, M. F. Princiotta, P. Berglund, J. Gibbs, J. R. Bennink, and J. W. Yewdell. 2004. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304:1318-1321.
34. Ourmanov, I., C. R. Brown, B. Moss, M. Carroll, L. Wyatt, L. Pletneva, S. Goldstein, D. Venzon, and V. M. Hirsch. 2000. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74:2740-2751.
35. mac-induced immunodeficiency. J. Virol. 76:292-302.
36. Pantaleo, G., and R. A. Koup. 2004. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10:806-810.
37. Peters, C., X. Peng, D. Douven, Z. K. Pan, and Y. Paterson. 2003. The induction of HIV Gag-specific CD8+ T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag. J. Immunol. 170:5176-5187.
38. Rock, M. T., and J. E. Crowe, Jr. 2003. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. Immunology 108:474-480.
39. Rose, N. F., P. A. Marx, A. Luckay, D. F. Nixon, W. J. Moretto, S. M. Donahoe, D. Montefiori, A. Roberts, L. Buonocore, and J. K. Rose. 2001. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539-549.
40. Sandefur, S., V. Varthakavi, and P. Spearman. 1998. The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag. J. Virol. 72:2723-2732.
41. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
42. Sigal, L. J., S. Crotty, R. Andino, and K. L. Rock. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398:77-80.
43. Spearman, P. 2003. HIV vaccine development: lessons from the past and promise for the future. Curr. HIV Res. 1:101-200.
44. Spearman, P., J. J. Wang, N. Vander Heyden, and L. Ratner. 1994. Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J. Virol. 68:3232-3242.
45. Stan, A. C., S. Casares, T. D. Brumeanu, D. M. Klinman, and C. A. Bona. 2001. CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes. Eur. J. Immunol. 31:301-310.
46. Strack, B., A. Calistri, S. Craig, E. Popova, and H. G. Gottlinger. 2003. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114:689-699.
47. Tartaglia, J., J. L. Excler, R. El Habib, K. Linibach, B. Meignier, S. Plotkin, and M. Klein. 1998. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res. Hum. Retrovir. 14(Suppl. 3):S291-S298.
48. von Schwedler, U. K., M. Stuchell, B. Muller, D. M. Ward, H. Y. Chung, E. Morita, H. E. Wang, T. Davis, G. P. He, D. M. Cimbora, A. Scott, H. G. Krausslich, J. Kaplan, S. G. Morham, and W. I. Sundquist. 2003. The protein network of HIV budding. Cell 114:701-713.
49. Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral Gag proteins. AIDS 5:639-654.